Prothena highlights positive Phase 2 Coramitug data published in AHA journal

Prothena (PRTA) announced the publication of Phase 2 clinical trial data for coramitug for the treatment of ATTR amyloidosis with cardiomyopathy in the American Heart Association’s journal, Circulation. The company noted the results were also presented at the AHA Scientific Sessions. Coramitug is being developed by Novo Nordisk (NVO), which recently initiated a Phase 3 trial for coramitug. Novo Nordisk gained full worldwide rights to the intellectual property and related rights of the ATTR amyloidosis business and pipeline it acquired from Prothena in July 2021. Under the terms of the acquisition agreement, Prothena is eligible to receive up to $1.2B upon achievement of clinical development and sales milestones, including $100M earned to date. Prothena is eligible to earn a clinical milestone payment when prespecified enrollment criteria are met in the CLEOPATTRA Phase 3 clinical trial.